Professional
Added to YB: 2025-01-30
Pitch date: 2025-01-28
MNMD [bullish]
Definium Therapeutics, Inc.
+133.69%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.
Market Cap
$1.6B
Pitch Price
$7.39
Price Target
23.00 (+33%)
Dividend
N/A
EV/EBITDA
-9.12
P/E
-7.97
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
Show full summary:
Evercore ISI Initiates Coverage on MindMed (MNMD) with Outperform Rating, $23 PT
MNMD: Evercore initiates Outperform, $23 PT. Novel oral LSD for GAD/MDD. Strong Ph2b data in GAD. Ph3 trials starting, data 1H/2H26. $1.8B target mkt cap, ~1.5x risk-adj peak sales. Huge markets: 35M+ GAD, 22M+ MDD in US. Psychedelics seen as future treatment paradigm in neuropsych.
Read full article (1 min)